Amantadine for antipsychotic-related weight gain: Meta-analysis of randomized placebo-controlled trials

Journal of Clinical Psychopharmacology

Volumn 37, Issue 3, 2017, Pages 341-346

  Zheng, Wei ^a   Wang, Shibin ^b   Ungvari, Gabor S ^c,d   Ng, Chee H ^e   Yang, Xin Hu ^a   Gu, Yu Hong ^f   Li, Ming ^a   Xiang, Ying Qiang ^g   Xiang, Yu Tao ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b University of Macau   (Macao)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Amantadine; Meta analysis; Schizophrenia; Weight gain

Indexed keywords

AMANTADINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONSTIPATION; DIZZINESS; DRUG WITHDRAWAL; DYSKINESIA; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; MONOTHERAPY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AMANTADINE; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 85017153004     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000598     Document Type: Article

References (31)

1. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105:175-187.
2. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks andmortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121.
3. Meyer JM. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010;4:23-42.
4. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophr Bull. 2014;40:1385-1403.
5. Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170:1032-1040.
6. ZhengW, Li XB, Tang YL, et al. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2015;35: 499-509.
7. Praharaj SK, Sharma PS. Amantadine for olanzapine-induced weight gain: A systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol. 2012;2:151-156.
8. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013;47:1143-1149.
9. Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol. 2002;12:249-257.
10. Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7:91-95.
11. FlorisM, Lejeune J, DeberdtW. Effect of amantadine onweight gain during olanzapine treatment. Eur Neuropsychopharmacol. 2001;11:181-182.
12. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005; 15:13-21.
13. Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744-1746.
14. JiWJ, Jiang X, Chen HY, et al. A randomized, double-blind and controlled study of olanzapine plus amantadine in patients with first episode schizophrenia [In Chinese]. J Clin Psychiatry. 2014;24:1-3.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13: 261-276.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
17. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
18. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
20. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271-275.
21. Silver H, Goodman C, Isakov V, et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol. 2005;20:319-326.
22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
23. Higgins JP, Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2008.
24. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406.
25. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1-12.
27. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.JClin Psychopharmacol. 1997;17:88-91.
28. Czepielewski LS, Sodré L, Souza AC, et al. Changes in verbal learning of patients with schizophrenia: results from a randomized, double-blind, placebo-controlled trial of amantadine adjunctive to antipsychotics. Schizophr Res. 2015;168:571-572.
29. DanyszW, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 1997;21:455-468.
30. Kornhuber J,WellerM, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91-104.
31. Silver H,Geraisy N. Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study. J Clin Psychopharmacol. 1996;16:463-464.